Do analysts prefer BCDA or BOLD?

BioCardia currently has a consensus price target of $25.00, indicating a potential upside of 2,303.85%. Given BioCardia's stronger consensus rating and higher probable upside, equities analysts clearly believe BioCardia is more favorable than Boundless Bio. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score BioCardia 1 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00 Boundless Bio 2 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Is BCDA or BOLD more profitable?

Boundless Bio's return on equity of -70.89% beat BioCardia's return on equity. Company Net Margins Return on Equity Return on Assets BioCardia N/A -569.36% -183.15% Boundless Bio N/A -70.89% -47.37%

Do analysts recommend BCDA or INMB?

BioCardia currently has a consensus price target of $25.00, suggesting a potential upside of 2,303.85%. Given BioCardia's higher probable upside, equities analysts plainly believe BioCardia is more favorable than INmune Bio. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score BioCardia 1 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00 INmune Bio 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 1 Strong Buy rating(s) 2.50

Which has higher valuation & earnings, BCDA or INMB?

BioCardia has higher revenue and earnings than INmune Bio. INmune Bio is trading at a lower price-to-earnings ratio than BioCardia, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio BioCardia $60K 262.43 -$8.23M -$0.64 N/A INmune Bio $50K 1,071.15 -$45.93M -$0.67 N/A

Is BCDA or INMB more profitable?

INmune Bio's return on equity of -82.87% beat BioCardia's return on equity. Company Net Margins Return on Equity Return on Assets BioCardia N/A -569.36% -183.15% INmune Bio N/A -82.87% -62.23%

Does the media refer more to BCDA or INMB?

In the previous week, BioCardia had 3 more articles in the media than INmune Bio. MarketBeat recorded 4 mentions for BioCardia and 1 mentions for INmune Bio. BioCardia's average media sentiment score of 0.75 beat INmune Bio's score of 0.75 indicating that BioCardia is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment BioCardia 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive INmune Bio 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts recommend BCDA or KVAC?

BioCardia presently has a consensus target price of $25.00, suggesting a potential upside of 2,303.85%. Given BioCardia's higher probable upside, equities research analysts clearly believe BioCardia is more favorable than Keen Vision Acquisition. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score BioCardia 1 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00 Keen Vision Acquisition 0 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00

Which has preferable earnings and valuation, BCDA or KVAC?

Keen Vision Acquisition has lower revenue, but higher earnings than BioCardia. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio BioCardia $60K 262.43 -$8.23M -$0.64 N/A Keen Vision Acquisition N/A N/A N/A N/A N/A

Is BCDA or KVAC more profitable?

Keen Vision Acquisition's return on equity of 0.00% beat BioCardia's return on equity. Company Net Margins Return on Equity Return on Assets BioCardia N/A -569.36% -183.15% Keen Vision Acquisition N/A N/A N/A

Is INKT or BCDA more profitable?

MiNK Therapeutics' return on equity of 0.00% beat BioCardia's return on equity. Company Net Margins Return on Equity Return on Assets MiNK Therapeutics N/A N/A -92.37% BioCardia N/A -569.36% -183.15%

Does the media prefer INKT or BCDA?

In the previous week, MiNK Therapeutics had 2 more articles in the media than BioCardia. MarketBeat recorded 6 mentions for MiNK Therapeutics and 4 mentions for BioCardia. BioCardia's average media sentiment score of 0.75 beat MiNK Therapeutics' score of 0.45 indicating that BioCardia is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment MiNK Therapeutics 1 Very Positive mention(s) 1 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral BioCardia 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts rate XLO or BCDA?

BioCardia has a consensus target price of $25.00, suggesting a potential upside of 2,303.85%. Given BioCardia's stronger consensus rating and higher probable upside, analysts clearly believe BioCardia is more favorable than Xilio Therapeutics. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Xilio Therapeutics 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 BioCardia 1 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00

Does the media prefer XLO or BCDA?

In the previous week, Xilio Therapeutics and Xilio Therapeutics both had 4 articles in the media. BioCardia's average media sentiment score of 0.75 beat Xilio Therapeutics' score of 0.00 indicating that BioCardia is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Xilio Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral BioCardia 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

BioCardia (BCDA) Competitors

$1.04 +0.02 (+1.96%)

Closing price 10/2/2026 04:00 PM Eastern

Extended Trading

$1.04 +0.00 (+0.48%)

As of 10/2/2026 04:10 PM Eastern

Compare

BCDA vs. BOLD, INMB, KVAC, INKT, and XLO

Should you buy BioCardia stock or one of its competitors? BioCardia's main competitors and comparable companies include Boundless Bio (BOLD), INmune Bio (INMB), Keen Vision Acquisition (KVAC), MiNK Therapeutics (INKT), and Xilio Therapeutics (XLO). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does BioCardia compare to Boundless Bio?

BioCardia (NASDAQ:BCDA) and Boundless Bio (NASDAQ:BOLD) are both small-cap healthcare companies, but which is the better business? We will compare the two companies based on the strength of their risk, institutional ownership, media sentiment, profitability, earnings, valuation, dividends and analyst recommendations.

BioCardia has higher revenue and earnings than Boundless Bio. BioCardia is trading at a lower price-to-earnings ratio than Boundless Bio, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
BioCardia	$60K	262.43	-$8.23M	-$0.64	N/A
Boundless Bio	N/A	N/A	-$58.20M	-$2.86	N/A

20.6% of BioCardia shares are owned by institutional investors. 17.4% of BioCardia shares are owned by insiders. Comparatively, 23.1% of Boundless Bio shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Boundless Bio's return on equity of -70.89% beat BioCardia's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
BioCardia	N/A	-569.36%	-183.15%
Boundless Bio	N/A	-70.89%	-47.37%

BioCardia has a beta of 0.62, suggesting that its stock price is 38% less volatile than the broader market. Comparatively, Boundless Bio has a beta of 0.02, suggesting that its stock price is 98% less volatile than the broader market.

In the previous week, BioCardia had 4 more articles in the media than Boundless Bio. MarketBeat recorded 4 mentions for BioCardia and 0 mentions for Boundless Bio. BioCardia's average media sentiment score of 0.75 beat Boundless Bio's score of 0.00 indicating that BioCardia is being referred to more favorably in the media.

Company	Overall Sentiment
BioCardia	Positive
Boundless Bio	Neutral

BioCardia currently has a consensus price target of $25.00, indicating a potential upside of 2,303.85%. Given BioCardia's stronger consensus rating and higher probable upside, equities analysts clearly believe BioCardia is more favorable than Boundless Bio.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
BioCardia	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Boundless Bio	2 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Summary

BioCardia beats Boundless Bio on 10 of the 14 factors compared between the two stocks.

How does BioCardia compare to INmune Bio?

BioCardia (NASDAQ:BCDA) and INmune Bio (NASDAQ:INMB) are both small-cap healthcare companies, but which is the better stock? We will compare the two businesses based on the strength of their profitability, media sentiment, analyst recommendations, dividends, valuation, risk, institutional ownership and earnings.

BioCardia has higher revenue and earnings than INmune Bio. INmune Bio is trading at a lower price-to-earnings ratio than BioCardia, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
BioCardia	$60K	262.43	-$8.23M	-$0.64	N/A
INmune Bio	$50K	1,071.15	-$45.93M	-$0.67	N/A

BioCardia currently has a consensus price target of $25.00, suggesting a potential upside of 2,303.85%. Given BioCardia's higher probable upside, equities analysts plainly believe BioCardia is more favorable than INmune Bio.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
BioCardia	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
INmune Bio	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	1 Strong Buy rating(s)	2.50

INmune Bio's return on equity of -82.87% beat BioCardia's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
BioCardia	N/A	-569.36%	-183.15%
INmune Bio	N/A	-82.87%	-62.23%

In the previous week, BioCardia had 3 more articles in the media than INmune Bio. MarketBeat recorded 4 mentions for BioCardia and 1 mentions for INmune Bio. BioCardia's average media sentiment score of 0.75 beat INmune Bio's score of 0.75 indicating that BioCardia is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
BioCardia	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
INmune Bio	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

20.6% of BioCardia shares are held by institutional investors. Comparatively, 12.7% of INmune Bio shares are held by institutional investors. 17.4% of BioCardia shares are held by company insiders. Comparatively, 21.4% of INmune Bio shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

BioCardia has a beta of 0.62, meaning that its share price is 38% less volatile than the broader market. Comparatively, INmune Bio has a beta of 0.89, meaning that its share price is 11% less volatile than the broader market.

Summary

BioCardia beats INmune Bio on 9 of the 16 factors compared between the two stocks.

How does BioCardia compare to Keen Vision Acquisition?

BioCardia (NASDAQ:BCDA) and Keen Vision Acquisition (NASDAQ:KVAC) are both small-cap healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their dividends, analyst recommendations, risk, media sentiment, institutional ownership, earnings, valuation and profitability.

BioCardia presently has a consensus target price of $25.00, suggesting a potential upside of 2,303.85%. Given BioCardia's higher probable upside, equities research analysts clearly believe BioCardia is more favorable than Keen Vision Acquisition.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
BioCardia	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Keen Vision Acquisition	0 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	2.00

20.6% of BioCardia shares are held by institutional investors. Comparatively, 51.7% of Keen Vision Acquisition shares are held by institutional investors. 17.4% of BioCardia shares are held by insiders. Comparatively, 80.2% of Keen Vision Acquisition shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

BioCardia has a beta of 0.62, meaning that its stock price is 38% less volatile than the broader market. Comparatively, Keen Vision Acquisition has a beta of -0.04, meaning that its stock price is 104% less volatile than the broader market.

In the previous week, BioCardia had 4 more articles in the media than Keen Vision Acquisition. MarketBeat recorded 4 mentions for BioCardia and 0 mentions for Keen Vision Acquisition. BioCardia's average media sentiment score of 0.75 beat Keen Vision Acquisition's score of 0.00 indicating that BioCardia is being referred to more favorably in the media.

Company	Overall Sentiment
BioCardia	Positive
Keen Vision Acquisition	Neutral

Keen Vision Acquisition's return on equity of 0.00% beat BioCardia's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
BioCardia	N/A	-569.36%	-183.15%
Keen Vision Acquisition	N/A	N/A	N/A

Keen Vision Acquisition has lower revenue, but higher earnings than BioCardia.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
BioCardia	$60K	262.43	-$8.23M	-$0.64	N/A
Keen Vision Acquisition	N/A	N/A	N/A	N/A	N/A

Summary

BioCardia beats Keen Vision Acquisition on 6 of the 10 factors compared between the two stocks.

How does BioCardia compare to MiNK Therapeutics?

MiNK Therapeutics (NASDAQ:INKT) and BioCardia (NASDAQ:BCDA) are both small-cap healthcare companies, but which is the better business? We will compare the two businesses based on the strength of their dividends, earnings, valuation, media sentiment, analyst recommendations, profitability, institutional ownership and risk.

In the previous week, MiNK Therapeutics had 2 more articles in the media than BioCardia. MarketBeat recorded 6 mentions for MiNK Therapeutics and 4 mentions for BioCardia. BioCardia's average media sentiment score of 0.75 beat MiNK Therapeutics' score of 0.45 indicating that BioCardia is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
MiNK Therapeutics	1 Very Positive mention(s)	1 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
BioCardia	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

MiNK Therapeutics' return on equity of 0.00% beat BioCardia's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
MiNK Therapeutics	N/A	N/A	-92.37%
BioCardia	N/A	-569.36%	-183.15%

MiNK Therapeutics presently has a consensus price target of $35.00, suggesting a potential upside of 181.35%. BioCardia has a consensus price target of $25.00, suggesting a potential upside of 2,303.85%. Given BioCardia's higher possible upside, analysts clearly believe BioCardia is more favorable than MiNK Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
MiNK Therapeutics	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
BioCardia	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

2.9% of MiNK Therapeutics shares are owned by institutional investors. Comparatively, 20.6% of BioCardia shares are owned by institutional investors. 20.4% of MiNK Therapeutics shares are owned by insiders. Comparatively, 17.4% of BioCardia shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

BioCardia has higher revenue and earnings than MiNK Therapeutics. MiNK Therapeutics is trading at a lower price-to-earnings ratio than BioCardia, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
MiNK Therapeutics	N/A	N/A	-$12.49M	-$2.40	N/A
BioCardia	$60K	262.43	-$8.23M	-$0.64	N/A

MiNK Therapeutics has a beta of 0.47, suggesting that its stock price is 53% less volatile than the broader market. Comparatively, BioCardia has a beta of 0.62, suggesting that its stock price is 38% less volatile than the broader market.

Summary

BioCardia beats MiNK Therapeutics on 8 of the 12 factors compared between the two stocks.

How does BioCardia compare to Xilio Therapeutics?

Xilio Therapeutics (NASDAQ:XLO) and BioCardia (NASDAQ:BCDA) are both small-cap healthcare companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, analyst recommendations, profitability, institutional ownership, valuation, risk, dividends and media sentiment.

54.3% of Xilio Therapeutics shares are owned by institutional investors. Comparatively, 20.6% of BioCardia shares are owned by institutional investors. 7.5% of Xilio Therapeutics shares are owned by company insiders. Comparatively, 17.4% of BioCardia shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

BioCardia has a consensus target price of $25.00, suggesting a potential upside of 2,303.85%. Given BioCardia's stronger consensus rating and higher probable upside, analysts clearly believe BioCardia is more favorable than Xilio Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Xilio Therapeutics	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
BioCardia	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

BioCardia has lower revenue, but higher earnings than Xilio Therapeutics. Xilio Therapeutics is trading at a lower price-to-earnings ratio than BioCardia, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Xilio Therapeutics	$43.77M	1.35	-$35.04M	-$1.64	N/A
BioCardia	$60K	262.43	-$8.23M	-$0.64	N/A

In the previous week, Xilio Therapeutics and Xilio Therapeutics both had 4 articles in the media. BioCardia's average media sentiment score of 0.75 beat Xilio Therapeutics' score of 0.00 indicating that BioCardia is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Xilio Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
BioCardia	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

BioCardia has a net margin of 0.00% compared to Xilio Therapeutics' net margin of -34.06%. Xilio Therapeutics' return on equity of -71.99% beat BioCardia's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Xilio Therapeutics	-34.06%	-71.99%	-20.43%
BioCardia	N/A	-569.36%	-183.15%

Xilio Therapeutics has a beta of -0.15, suggesting that its stock price is 115% less volatile than the broader market. Comparatively, BioCardia has a beta of 0.62, suggesting that its stock price is 38% less volatile than the broader market.

Summary

BioCardia beats Xilio Therapeutics on 11 of the 15 factors compared between the two stocks.

Get BioCardia News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding BCDA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

BCDA vs. The Competition

Export

Metric	BioCardia	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$15.74M	$3.85B	$7.15B	$13.28B
Dividend Yield	N/A	3.65%	2.54%	17.33%
P/E Ratio	-1.63	13.00	275.67	26.04
Price / Sales	262.43	1,289.24	656.66	105.14
Price / Cash	N/A	123.39	78.87	52.62
Price / Book	13.00	16.57	10.93	6.31
Net Income	-$8.23M	-$22.66M	$3.51B	$362.16M
7 Day Performance	-0.95%	-2.97%	-2.00%	-1.66%
1 Month Performance	-3.70%	-10.82%	-6.19%	-4.68%
1 Year Performance	-23.53%	19.00%	8.03%	1.57%

BioCardia Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
BCDA BioCardia	3.8588 of 5 stars	$1.04 +2.0%	$25.00 +2,303.8%	-23.5%	$15.74M	$60K	N/A	21	News Coverage
BOLD Boundless Bio	0.7651 of 5 stars	$2.88 +1.8%	N/A	+115.6%	$64.38M	N/A	N/A	28	Positive News
INMB INmune Bio	0.7428 of 5 stars	$2.16 -5.7%	N/A	-7.2%	$63.56M	$50K	N/A	21	Positive News
KVAC Keen Vision Acquisition	N/A	$11.51 flat	N/A	N/A	$63.37M	N/A	N/A	N/A
INKT MiNK Therapeutics	2.8152 of 5 stars	$12.11 -1.1%	$35.00 +189.0%	-17.2%	$62.51M	N/A	N/A	15	News Coverage

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:BCDA) was last updated on 10/4/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

BioCardia (BCDA) Competitors

BCDA vs. BOLD, INMB, KVAC, INKT, and XLO

How does BioCardia compare to Boundless Bio?

Summary

How does BioCardia compare to INmune Bio?

Summary

How does BioCardia compare to Keen Vision Acquisition?

Summary

How does BioCardia compare to MiNK Therapeutics?

Summary

How does BioCardia compare to Xilio Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

BCDA vs. The Competition

BioCardia Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

BioCardia (BCDA) Competitors

BCDA vs. BOLD, INMB, KVAC, INKT, and XLO

How does BioCardia compare to Boundless Bio?

Which has better valuation and earnings, BCDA or BOLD?

Do insiders & institutionals believe in BCDA or BOLD?

Is BCDA or BOLD more profitable?

Which has more risk & volatility, BCDA or BOLD?

Does the media refer more to BCDA or BOLD?

Do analysts prefer BCDA or BOLD?

Summary

How does BioCardia compare to INmune Bio?

Which has higher valuation & earnings, BCDA or INMB?

Do analysts recommend BCDA or INMB?

Is BCDA or INMB more profitable?

Does the media refer more to BCDA or INMB?

Do insiders and institutionals have more ownership in BCDA or INMB?

Which has more risk & volatility, BCDA or INMB?

Summary

How does BioCardia compare to Keen Vision Acquisition?

Do analysts recommend BCDA or KVAC?

Do insiders & institutionals hold more shares of BCDA or KVAC?

Which has more volatility & risk, BCDA or KVAC?

Does the media refer more to BCDA or KVAC?

Is BCDA or KVAC more profitable?

Which has preferable earnings and valuation, BCDA or KVAC?

Summary

How does BioCardia compare to MiNK Therapeutics?

Does the media prefer INKT or BCDA?

Is INKT or BCDA more profitable?

Do analysts rate INKT or BCDA?

Do institutionals and insiders hold more shares of INKT or BCDA?

Which has better valuation & earnings, INKT or BCDA?

Which has more volatility & risk, INKT or BCDA?

Summary

How does BioCardia compare to Xilio Therapeutics?

Do institutionals & insiders hold more shares of XLO or BCDA?

Do analysts rate XLO or BCDA?

Which has higher earnings and valuation, XLO or BCDA?

Does the media prefer XLO or BCDA?

Is XLO or BCDA more profitable?

Which has more risk and volatility, XLO or BCDA?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

BCDA vs. The Competition

BioCardia Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools